Form 4: Supernus Director Sells Shares Under 10b5-1 Plan

Supernus Pharmaceuticals Director Charles W. Newhall III sold 1,412 shares of common stock for approximately $45.00 per share, executed under a pre-arranged 10b5-1 trading plan.

Summary

• Charles W. Newhall III, a Director of Supernus Pharmaceuticals, Inc. (SUPN), reported the sale of 1,412 shares of common stock.
• The transaction occurred on August 22, 2025, at a weighted average price of $45.00 per share, with individual sales ranging from $45.00 to $45.01.
• The sale was executed pursuant to a Rule 10b5-1 trading plan, which was adopted on March 3, 2025.
• Following this transaction, Mr. Newhall directly beneficially owns 134,232 shares of Supernus Pharmaceuticals common stock.

Sentiment

Score: 5

Explanation: The sale of shares by a director, while reducing their direct stake, was executed under a pre-arranged 10b5-1 trading plan, which typically signals a planned financial event rather than a reaction to new company-specific information, thus having a neutral impact on sentiment.

Positives

• The transaction was executed under a pre-arranged Rule 10b5-1 trading plan, indicating a scheduled financial event rather than a reaction to new, non-public company information.

Negatives

• A director selling shares, even under a 10b5-1 plan, reduces their direct ownership stake in the company.

Stakeholder Impact

• Shareholders: The sale represents a minor reduction in a director's direct ownership, which is generally viewed as neutral given the pre-planned nature of the transaction.

Key Dates

Recommendation

The Form 4 filing reports a routine insider transaction under a 10b5-1 plan. This type of pre-scheduled sale by a director does not typically provide new material information that would warrant a change in investment recommendation for Supernus Pharmaceuticals. Investors should consider broader company fundamentals and market conditions.

Keywords

SUPN, Supernus Pharmaceuticals, Form 4, Insider Transaction, Stock Sale, Director, 10b5-1 Plan